Summary & Overview
CPT 0496U: ColoScape Plus Blood Test for Colorectal Cancer Risk
CPT code 0496U identifies a Proprietary Laboratory Analyses (PLA) test: ColoScape™ Plus from DiaCarta Inc., a blood-based assay that uses RT–PCR and ELISA to evaluate cell-free DNA and protein markers for colorectal cancer or advanced adenoma risk. As a PLA code, 0496U is unique to a single manufacturer's commercial test and signals clinical use of proprietary molecular diagnostics in cancer screening and risk stratification. Nationally, PLA codes like 0496U matter because they affect payer coverage decisions, coding consistency, and access to emerging diagnostics.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, the service context for billing and claims, and what to expect in payer coverage conversations. The publication summarizes common modifiers associated with the code, outlines typical sites of service, and highlights the implications of PLA designation for coding and reimbursement processes. It also provides context on clinical utility for colorectal cancer risk assessment and how proprietary lab tests are captured in billing systems.
Data not provided in the input are identified explicitly where relevant (for example, associated taxonomies, specific ICD-10 diagnosis mappings, and related codes).
Billing Code Overview
CPT code 0496U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the ColoScape™ Plus test from DiaCarta Inc. The assay combines real–time reverse transcription polymerase chain reaction (RT–PCR) and enzyme–linked immunosorbent assay (ELISA) to analyze cell–free DNA and proteins in blood, providing an assessment of the risk for colorectal cancer or advanced adenoma.
Service type: Proprietary laboratory test using molecular and protein analysis to assess colorectal cancer risk
Typical site of service: Clinical laboratory or diagnostic testing facility (blood-based testing, phlebotomy performed in outpatient settings)
Clinical & Coding Specifications
Clinical Context
A typical patient is a 50–to–75‑year‑old adult with average to elevated risk for colorectal neoplasia who declines or is unable to undergo colonoscopy, or as an adjunct to screening when noninvasive blood‑based testing is selected. The clinician (gastroenterologist, primary care physician, or oncologist) orders the ColoScape™ Plus test (0496U) when evaluation of circulating cell‑free DNA mutations and protein biomarkers is desired to estimate risk of colorectal cancer or advanced adenoma. The clinical workflow: the patient presents to an outpatient phlebotomy site or clinical laboratory for venipuncture; a laboratory requisition specifying test 0496U is completed and the blood specimen is collected, processed, and shipped per the manufacturer's instructions; the laboratory performs RT‑PCR and ELISA analyses on cell‑free DNA and proteins; a consolidated report with risk stratification is generated and returned to the ordering provider; the clinician reviews results with the patient to determine need for diagnostic colonoscopy or intensified surveillance. Typical site of service is outpatient laboratory, physician office with phlebotomy, or ambulatory surgical center coordinating follow‑up colonoscopy if indicated. Common patient scenarios include: surveillance in patients with prior adenoma, evaluation of occult symptoms (unexplained iron deficiency anemia or rectal bleeding), or alternative screening for patients refusing colonoscopy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |